Based on evidence that cannabinoids and opioids can work in synergy to moderate pain, Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) and its research arm, Cannevert Therapeutics Ltd., intend to boost actions of opioid analgesics with a specific strain of cannabis. A recent article highlights the company’s approach in developing quality strains, stating, “Veritas … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) to Leverage Unique Compound Synergies for Pain Moderation”
Unique scientific approach lends more credibility and increases consumer confidence Huge potential for cannabis to replace opioids as analgesics Strategic partnerships position Veritas strongly in the medical cannabis industry On September 13, 2017, Cannevert Therapeutics Ltd. (“CTL”), the research arm of Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), filed a provisional patent for … Continue reading “Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Aims to Enhance Opioid Analgesic Effects with Specific Cannabis Strain”
Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is using scientific research and development to stake out its spot in the medical marijuana industry. An article discussing this reads: “Veritas Pharma’s mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Develops Cannabis-Based Therapeutics in Response to Opioid Epidemic”
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning reported that the company has hired Dr. M. Scott Alexander as a medical director. Alexander’s role will be to confirm the medical integrity of cannabis research programs conducted by the company’s subsidiary, Cannevert Therapeutics Ltd. In addition, Alexander will develop a medical affairs strategy to … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Retains Medical Director to Advise Cannabis Research Programs”
Veritas Pharma is unlocking the science underlying medical cannabis Clinically profiling select cannabis strains – pharmacologically identifying strains for specific disease conditions Entering human clinical studies with valuable IP’s in place There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the … Continue reading “Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Providing Clinical Proof of Cannabis Efficiency”
Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. Per the agreement, the Institute for Medical Cannabis will provide CTL with particular cannabis strains … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Cannevert Subsidiary Inks Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico”
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), received an acknowledgement letter with the filing number of US 62/558,021 from the US Patent and Trademark Office (“USPTO”) for the filing it made in September for use of a specific cannabis strain to enhance the actions … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Research Arm’s Patent Filing for Use of Specific Cannabis Strain Acknowledged by US Patent Office”
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) recently announced that its 80% owned subsidiary, Cannevert Therapeutics Ltd. (“CTL”), signed a letter of intent with the Fundación de Investigación (“FDI”) in San Juan, Puerto Rico, to conduct the first human study of CTL-X for the treatment of pain. The study of CTL-X, CTL’s lead cannabis … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc.’s (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) CTL Subsidiary Inks Letter of Intent with FDI of Puerto Rico to Initiate Human Trials of CTL-X”
Management, R&D team boasts decades of industry leadership Pipeline includes therapies targeting chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder Unique result-driven strategy strongly positions Veritas in the medical marijuana industry Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is an emerging pharmaceutical and IP development company publicly traded in Canada, the … Continue reading “Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is “One to Watch””
NetworkNewsWire Editorial Coverage: With cannabis set to become legal for recreational use in July 2018 in Canada, and usage of the product for medical purposes steadily rising both in Canada and worldwide, cannabis companies have ramped up their efforts to make new scientific discoveries related to the plant’s medical uses. Companies leading the quest to … Continue reading “Investors Could Reap Global Rewards of Research into Medical Cannabis Science”
